Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Murthy

Showing results (751-760 of 873) with videos related to

Pageof 88
Sort By:
Clinical Breast Cancer|July 10, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 StudyShanu Modi, Rashmi K Murthy, A Jo Chien, et al.
International Journal of Molecular Medicine|June 9, 2005
Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infectionLewis F Neville, Yoav Barnea, Orly Hammer-Munz, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Journal of Virology|October 1, 1996
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateA J Conley, J A Kessler, L J Boots, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
American Journal of Respiratory Cell and Molecular Biology|November 5, 2024
Novel Porcine Model Reveals Two Distinct LGR5 Cell Types during Lung Development and HomeostasisKathryn M Polkoff, Ross Lampe, Nithin K Gupta, et al.
AIDS Research and Human Retroviruses|September 20, 1996
Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzeesK K Murthy, E K Cobb, Z el-Amad, et al.
Cancer Discovery|July 27, 2013
PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapyJing Tan, Zhimei Li, Puay Leng Lee, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|July 6, 2013
Therapeutic interventions and short-term outcomes for infants with severe bronchopulmonary dysplasia born at <32 weeks' gestationM A Padula, T R Grover, B Brozanski, et al.
Journal of Crohn'S & Colitis|July 11, 2020
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related ComplicationsLaura E Targownik, Eric I Benchimol, Charles N Bernstein, et al.
Pageof 88

Showing results (751-760 of 873) with videos related to

Sort By:
Pageof 88
Clinical Breast Cancer|July 10, 2026
Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 StudyShanu Modi, Rashmi K Murthy, A Jo Chien, et al.
International Journal of Molecular Medicine|June 9, 2005
Antibodies raised against N'-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infectionLewis F Neville, Yoav Barnea, Orly Hammer-Munz, et al.
The Oncologist|February 1, 2020
Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without TrastuzumabTakahiro Kogawa, Takeo Fujii, Jimin Wu, et al.
Journal of Virology|October 1, 1996
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolateA J Conley, J A Kessler, L J Boots, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast CancerG Travis Clifton, Diane Hale, Timothy J Vreeland, et al.
American Journal of Respiratory Cell and Molecular Biology|November 5, 2024
Novel Porcine Model Reveals Two Distinct LGR5 Cell Types during Lung Development and HomeostasisKathryn M Polkoff, Ross Lampe, Nithin K Gupta, et al.
AIDS Research and Human Retroviruses|September 20, 1996
Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzeesK K Murthy, E K Cobb, Z el-Amad, et al.
Cancer Discovery|July 27, 2013
PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapyJing Tan, Zhimei Li, Puay Leng Lee, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|July 6, 2013
Therapeutic interventions and short-term outcomes for infants with severe bronchopulmonary dysplasia born at <32 weeks' gestationM A Padula, T R Grover, B Brozanski, et al.
Journal of Crohn'S & Colitis|July 11, 2020
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related ComplicationsLaura E Targownik, Eric I Benchimol, Charles N Bernstein, et al.
Pageof 88